Blockade of Surface Alpha-Enolase (ENO1) as a Novel Immunotherapeutic Approach in Pancreatic CancerMoitza Principe1,2, Paola Cappello1,2,3 and Francesco Novelli1,2,3,4*
- *Corresponding Author:
- Francesco Novelli
Center for Experimental Research and Medical Studies (CeRMS)
Azienda Universitaria Ospedaliera Città della
Salute e della Scienza di Torino, Turin, Italy
E-mail: [email protected]
Received date: January 11, 2016; Accepted date: February 15, 2016; Published date: February 20, 2016
Citation: Principe M, Cappello P, Novelli F (2016) Blockade of Surface Alpha-Enolase (ENO1) as a Novel Immunotherapeutic Approach in Pancreatic Cancer. Chemo Open Access 5:188. doi:10.4172/2167-7700.1000188
Copyright: © 2016 Principe M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In 2010 in Italy, there were 175,046 cancer deaths, with total mortality rates, respectively for men and women, of 138 and 83/100,000 . Total cancer mortality in Italy has been declining since the 1980s in men and earlier in women , similarly to most European countries  and the United States . However, some rising trends have also been observed, notably for female lung cancer and pancreatic cancer in both sexes . Although the incidence of pancreatic cancer is relative low compared to other tumor types such as breast, lung and prostate cancer, in pancreatic cancer the mortality is almost equal to the incidence level, with 41,780 and 40,560 deaths predicted in Europe and USA respectively [2,4]. For this reason, PDA is the 4th leading cause of cancer deaths in the Western Countries [1,2,4]. Despite the efforts of clinicians and scientists, pancreatic cancer has the worst prognosis of all major malignancies, with a 5-year survival rate of 8% .